IN2014MN01571A - - Google Patents
Info
- Publication number
- IN2014MN01571A IN2014MN01571A IN1571MUN2014A IN2014MN01571A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A IN 1571MUN2014 A IN1571MUN2014 A IN 1571MUN2014A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A
- Authority
- IN
- India
- Prior art keywords
- ocular
- steroid
- pharmaceutical composition
- composition
- umol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000003431 steroids Chemical class 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids with or without cholesterol and a steroid solution comprising an ocular steroid derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5umol per 50ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597189P | 2012-02-10 | 2012-02-10 | |
| PCT/US2013/025390 WO2013119988A1 (en) | 2012-02-10 | 2013-02-08 | Pharmaceutical compositions to reduce complications of ocular steroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01571A true IN2014MN01571A (en) | 2015-05-15 |
Family
ID=48948063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1571MUN2014 IN2014MN01571A (en) | 2012-02-10 | 2013-02-08 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10058616B2 (en) |
| EP (1) | EP2797601B1 (en) |
| JP (1) | JP6231995B2 (en) |
| KR (1) | KR102060210B1 (en) |
| CN (2) | CN107260679B (en) |
| AU (1) | AU2013216861B2 (en) |
| BR (1) | BR112014018393B1 (en) |
| CA (1) | CA2862055C (en) |
| CY (1) | CY1120323T1 (en) |
| DK (1) | DK2797601T3 (en) |
| ES (1) | ES2673330T3 (en) |
| IN (1) | IN2014MN01571A (en) |
| NZ (1) | NZ628124A (en) |
| PT (1) | PT2797601T (en) |
| RU (1) | RU2660585C2 (en) |
| TR (1) | TR201808592T4 (en) |
| TW (1) | TWI620578B (en) |
| WO (1) | WO2013119988A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111415822A (en) * | 2020-03-05 | 2020-07-14 | 沈阳农业大学 | A kind of onion carbon/manganese dioxide array electrode and preparation method and application thereof |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190133931A1 (en) * | 2016-04-19 | 2019-05-09 | Nanyang Technological University | Subconjunctival depot forming formulations for ocular drug delivery |
| WO2019060696A1 (en) | 2017-09-25 | 2019-03-28 | Surface Pharmaceuticals, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| AU2018372185B2 (en) * | 2017-11-21 | 2024-05-16 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| CN112469420A (en) * | 2018-07-09 | 2021-03-09 | 台湾微脂体股份有限公司 | Method for reducing complications of steroids in joints |
| KR20210060559A (en) | 2018-09-16 | 2021-05-26 | 티엘씨 바이오파머슈티컬즈 인코포레이티드 | Pharmaceutical compositions suitable for joint delivery and their use in the treatment of joint pain |
| CN113473970A (en) | 2018-12-27 | 2021-10-01 | 瑟菲斯眼科股份有限公司 | Ophthalmic pharmaceutical compositions and methods for treating ocular surface diseases |
| RU2716429C1 (en) * | 2019-05-29 | 2020-03-11 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Method of treating recurrent erosion of corneas of various origins |
| WO2022240598A1 (en) | 2021-05-10 | 2022-11-17 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| SE9100342D0 (en) | 1991-02-04 | 1991-02-04 | Astra Ab | NOVEL STEROID ESTERS |
| IL103907A0 (en) * | 1992-11-27 | 1993-04-04 | Pharmos Corp | Ophthalmic compositions |
| WO2004047800A2 (en) * | 2002-11-26 | 2004-06-10 | Gilead Sciences, Inc. | Method of drug loading in liposomes by gradient |
| WO2004069284A2 (en) | 2003-02-04 | 2004-08-19 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
| KR100862930B1 (en) * | 2004-06-23 | 2008-10-13 | 시리온 테라퓨틱스, 인크. | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| EP2322183B1 (en) | 2006-06-01 | 2014-10-22 | Santen SAS | Use of prodrugs for ocular intravitreous administration |
| MX2008016167A (en) * | 2006-06-22 | 2009-02-10 | Sirion Therapeutics Inc | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity. |
| US20080118500A1 (en) * | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
| EP2255788B1 (en) * | 2008-02-29 | 2015-07-22 | Nagoya Industrial Science Research Institute | Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye |
| CN101502485A (en) * | 2009-03-20 | 2009-08-12 | 中国药科大学 | Nano cubic liquid crystal dexamethasone preparation for eye and preparation method thereof |
| CN101926769A (en) | 2009-06-24 | 2010-12-29 | 天津金耀集团有限公司 | Dexamethasone Sodium Phosphate Liposome Injection |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| WO2011115684A2 (en) * | 2010-03-19 | 2011-09-22 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| US20130217657A1 (en) * | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2013
- 2013-02-08 CN CN201710573136.5A patent/CN107260679B/en active Active
- 2013-02-08 IN IN1571MUN2014 patent/IN2014MN01571A/en unknown
- 2013-02-08 EP EP13747021.7A patent/EP2797601B1/en active Active
- 2013-02-08 WO PCT/US2013/025390 patent/WO2013119988A1/en not_active Ceased
- 2013-02-08 AU AU2013216861A patent/AU2013216861B2/en active Active
- 2013-02-08 BR BR112014018393-7A patent/BR112014018393B1/en active IP Right Grant
- 2013-02-08 US US14/377,211 patent/US10058616B2/en active Active
- 2013-02-08 TW TW102105245A patent/TWI620578B/en active
- 2013-02-08 DK DK13747021.7T patent/DK2797601T3/en active
- 2013-02-08 CA CA2862055A patent/CA2862055C/en active Active
- 2013-02-08 KR KR1020147022121A patent/KR102060210B1/en active Active
- 2013-02-08 NZ NZ628124A patent/NZ628124A/en unknown
- 2013-02-08 RU RU2014132553A patent/RU2660585C2/en active
- 2013-02-08 ES ES13747021.7T patent/ES2673330T3/en active Active
- 2013-02-08 TR TR2018/08592T patent/TR201808592T4/en unknown
- 2013-02-08 PT PT137470217T patent/PT2797601T/en unknown
- 2013-02-08 CN CN201380008147.9A patent/CN104125830B/en active Active
- 2013-02-08 JP JP2014556741A patent/JP6231995B2/en active Active
-
2018
- 2018-03-06 US US15/913,466 patent/US10350294B2/en active Active
- 2018-06-11 CY CY20181100606T patent/CY1120323T1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111415822A (en) * | 2020-03-05 | 2020-07-14 | 沈阳农业大学 | A kind of onion carbon/manganese dioxide array electrode and preparation method and application thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ628124A (en) | Pharmaceutical compositions to reduce complications of ocular steroid | |
| WO2012021107A3 (en) | A liposomal formulation for ocular drug delivery | |
| DOP2012000225A (en) | PIRROLO-PYRIMIDINE COMPOUNDS AS CDK4 / 6 INHIBITORS | |
| AR091006A1 (en) | PROLIPOSOMAL TESTOSTERONE FORMULATIONS | |
| NZ732777A (en) | Ionizable cationic lipid for rna delivery | |
| BR112015022476A2 (en) | Liposome Oxaliplatin Compositions for Cancer Therapy | |
| AR084932A1 (en) | OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY | |
| MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
| EA201400392A1 (en) | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPIRIDAZINES AS AGONISTS Rev-Erb | |
| IN2014DN00277A (en) | ||
| WO2008070463A3 (en) | Endoxifen methods and compositions | |
| PH12014500510A1 (en) | Use of omega fatty acids for treating disease | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112015022415A2 (en) | Liposomal cisplatin compositions for cancer therapy | |
| BR112014015333A2 (en) | chlorite or chlorate liposomal compositions | |
| CA2854430C (en) | Liposomal corticosteroids for treatment of inflammatory disorders in humans | |
| NZ718185A (en) | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | |
| DOP2013000314A (en) | TYPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB | |
| MX376783B (en) | Liposome-based immunotherapy | |
| BR112014004732A2 (en) | benzothiazolone compound | |
| WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
| MX2009009171A (en) | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome. | |
| MX350662B (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl) -5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions. | |
| BR112014001503A2 (en) | pharmaceutical compositions comprising 4-bromo-n- (imidazolidin-2-ylidene) -1h-benzimidazol-5-amine for the treatment of skin diseases | |
| MX2019015712A (en) | Crystalline forms of beta-sitosterol. |